PUBLISHER: Acute Market Reports | PRODUCT CODE: 1510285
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1510285
Targeted Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
Targeted therapeutics refers to drugs and treatments specifically designed to target particular molecular pathways that are associated with diseases, most commonly cancers. These therapies aim to selectively affect diseased cells while minimizing damage to normal cells, enhancing treatment efficacy and reducing side effects compared to conventional treatments. Targeted therapeutics include various types such as monoclonal antibodies, small molecule inhibitors, and ligand-receptor interactions. These drugs work by interacting with specific biomarkers or genetic mutations within disease cells, offering a personalized approach to treatment.
The targeted therapeutics market is experiencing significant growth, with a projected compound annual growth rate (CAGR) of 6.2% from 2024 to 2032. This growth is largely driven by the increasing incidence of chronic diseases such as cancer, coupled with advancements in molecular biology and genomics that have improved the understanding of disease mechanisms at the molecular level. These advancements have facilitated the development of new targeted therapies that can more precisely address the underlying causes of diseases. Moreover, the shift towards personalized medicine is significantly influencing the market. As medical treatment becomes more customized to individual patient profiles, targeted therapeutics are becoming increasingly important for their ability to provide tailored treatment options based on genetic, biomarker, and phenotypic characteristics that predict individual responses to therapies. The market is also supported by robust investment in R&D by pharmaceutical companies, government initiatives to streamline drug approval processes, and a growing demand for more effective treatment regimens with fewer side effects. Despite high development costs and complex regulatory environments, the targeted therapeutics market continues to expand, promising new effective treatment paradigms for patients worldwide.
Advancements in Genomic Profiling
A significant driver for the targeted therapeutics market is the rapid advancements in genomic profiling technologies. The ability to decode and interpret genetic data has drastically improved, allowing researchers and healthcare providers to identify specific genetic mutations and biomarkers associated with various diseases, particularly cancers. Techniques such as next-generation sequencing (NGS) and CRISPR have revolutionized the field of genomics, making it quicker, cheaper, and more accurate to perform detailed genetic analyses. These developments have facilitated the design of targeted therapies that specifically attack cancer cells based on their unique genetic characteristics, improving treatment efficacy and reducing side effects. The rising prevalence of cancers and the subsequent need for effective treatments continue to drive investments and innovations in this area, underscoring the pivotal role of genomics in advancing personalized medicine.
Expansion in Emerging Markets
The targeted therapeutics market presents substantial opportunities for expansion into emerging markets. Countries like China, India, and Brazil are rapidly developing their healthcare infrastructure and regulatory frameworks to support advanced medical treatments, including targeted therapies. These markets offer a vast patient base and are experiencing increasing healthcare expenditure alongside growing awareness about cancer and its modern treatments. Pharmaceutical companies are recognizing the potential in these regions for growth due to lower operational and labor costs, which can facilitate local production and distribution of targeted therapies. The ongoing globalization of healthcare standards and practices, along with collaborations between Western and local pharmaceutical companies, is expected to further enhance market penetration and adoption of targeted therapeutics in these emerging markets.
High Cost of Treatment
A major restraint in the targeted therapeutics market is the high cost associated with developing and administering these treatments. Targeted drugs often require extensive and expensive research and development phases, involving complex clinical trials designed to test their efficacy and safety across specific patient populations. Furthermore, the production of these therapies involves sophisticated technologies and highly regulated manufacturing processes, contributing to higher end-product prices. For many patients, especially in less developed countries, the high cost of targeted therapies limits accessibility and poses significant challenges for healthcare systems to provide these advanced treatments. Insurance coverage and reimbursement levels also vary widely, which can prevent patients from receiving potentially life-saving therapies.
Regulatory Hurdles and Market Approval
A significant challenge facing the targeted therapeutics market is navigating the complex regulatory environment required for new drug approvals. Each targeted therapy must undergo rigorous evaluation by regulatory bodies such as the FDA and EMA, which scrutinize the drug's effectiveness, safety, and manufacturing consistency. The precision of targeted therapies means that any slight variation in production can alter a drug's composition and its interaction with the body, necessitating stringent quality controls and compliance with regulatory standards. Additionally, the approval process can be lengthy and costly, discouraging innovation and delaying the availability of new treatments. Companies must also keep up with evolving regulations and possibly adapt their development strategies accordingly, which adds to the complexity and cost of bringing targeted therapeutics to market.
Market Segmentation by Type
In the targeted therapeutics market, segmentation by type includes Monoclonal Antibodies (such as Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) and Small Molecules (primarily Tyrosine Kinase Inhibitors). Monoclonal antibodies have consistently generated the highest revenue within the market due to their broad applicability in various cancer treatments and autoimmune diseases. Their specificity in targeting diseased cells while sparing healthy ones makes them a dominant choice in oncology and immunology. Among these, HER-2 targeted agents, which are used extensively in breast cancer treatment, have been particularly lucrative. However, the highest CAGR is projected for Small Molecule inhibitors, especially Tyrosine Kinase Inhibitors, driven by their growing use in treating chronic diseases with high prevalence rates, such as lung and renal cancers. These inhibitors are becoming increasingly popular due to their ability to target specific molecular pathways involved in cancer cell growth and survival, coupled with their oral bioavailability, which offers easier administration compared to injectable therapies.
Market Segmentation by Application
Regarding segmentation by application, the market includes treatment areas such as Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, Renal Cancer, and Wet Age-related Macular Degeneration, among others (including Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer). Breast cancer treatment has generated the highest revenue, largely due to the prevalence of the disease and the effectiveness of targeted therapies like HER-2 inhibitors in improving patient outcomes. Lung cancer, however, is expected to exhibit the highest CAGR owing to the increasing incidence globally and the development of novel targeted therapies that address specific genetic mutations in lung cancer cells, such as ALK or EGFR inhibitors, which are significantly transforming the treatment landscape of this disease.
Market Segmentation by Distribution Channels
In terms of distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies have historically accounted for the highest revenue in the distribution of targeted therapeutics because these therapies often require professional medical oversight during administration, especially for complex cancers and autoimmune diseases treated in hospital settings. On the other hand, online pharmacies are expected to witness the highest CAGR from 2024 to 2032. This growth is driven by the increasing consumer preference for convenience, lower costs, and the rising penetration of internet and e-commerce platforms that offer direct-to-patient sales models, making it easier for patients to access their medications amid ongoing advancements in digital health technologies.
Regional Insights
In 2023, the targeted therapeutics market was heavily dominated by North America, primarily due to the region's advanced healthcare infrastructure, robust R&D capabilities, and high healthcare expenditure which facilitated the adoption of advanced cancer treatments and personalized medicine. North America also benefited from having a regulatory environment that actively supports the fast-tracking of breakthrough therapies. However, Asia-Pacific is expected to exhibit the highest CAGR from 2024 to 2032. This growth is driven by increasing healthcare spending, rising awareness of targeted therapies, and improvements in healthcare infrastructure across major economies such as China and India. Moreover, these regions are seeing a surge in local biotech developments and government support for precision medicine initiatives.
Competitive Trends
The competitive landscape in the targeted therapeutics market featured intense activities from key players such as Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., and Bristol-Myers Squibb Company. In 2023, these companies focused on strategic collaborations, mergers, and acquisitions to enhance their market presence and expand their therapeutic portfolios. For instance, collaborations between companies like Pfizer and smaller biotech firms were common to leverage innovative technologies for drug development. Investment in research and development was particularly robust, with a strong emphasis on oncology and autoimmune diseases where targeted therapies can provide significant patient benefits. From 2024 to 2032, it is expected that these companies will continue to expand their global footprints, particularly in emerging markets where there is substantial growth potential. Strategies will likely include forming partnerships with local companies to navigate regulatory landscapes more effectively and to gain access to local distribution networks. Moreover, as patent cliffs approach for several key biologics, companies are anticipated to intensify their focus on developing biosimilars and next-generation biologics to sustain revenue streams and address competitive pressures. Emphasis on personalized medicine is also expected to increase, driving further innovation in targeted therapies and companion diagnostics to enhance treatment efficacy and safety profiles. The competitive dynamics in this period are likely to be shaped by technological advancements, regulatory changes, and evolving healthcare policies that emphasize cost-effectiveness and patient outcomes.
Historical & Forecast Period
This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Targeted Therapeutics market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users & consumption volume, price, and value.
Geographical revenues generated by countries considered in the report
Micro and macro environment factors that are currently influencing the Targeted Therapeutics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.
Market Segmentation
Type
- Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies)
- Small Molecule (Tyrosine Kinase Inhibitors)
Application
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Sclerosis
- Renal Cancer
- Wet Age-related Macular Degeneration
- Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region Segment (2022-2032; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Targeted Therapeutics market?
What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2032.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Targeted Therapeutics market?
Which is the largest regional market for Targeted Therapeutics market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Targeted Therapeutics market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Targeted Therapeutics market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Targeted Therapeutics Market
- 2.2. Global Targeted Therapeutics Market, By Type, 2023 (US$ Million)
- 2.3. Global Targeted Therapeutics Market, By Application, 2023 (US$ Million)
- 2.4. Global Targeted Therapeutics Market, By Distribution Channel, 2023 (US$ Million)
- 2.5. Global Targeted Therapeutics Market, By Geography, 2023 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2023
3. Targeted Therapeutics Market: Competitive Analysis
- 3.1. Market Positioning of Key Targeted Therapeutics Market Vendors
- 3.2. Strategies Adopted by Targeted Therapeutics Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2023 Versus 2032
4. Targeted Therapeutics Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Targeted Therapeutics Market Value, 2022 - 2032, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2023 Versus 2032
- 5.3. Market Segmentation
- 5.3.1. Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies)
- 5.3.2. Small Molecule (Tyrosine Kinase Inhibitors)
6. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2023 Versus 2032
- 6.3. Market Segmentation
- 6.3.1. Breast Cancer
- 6.3.2. Colorectal Cancer
- 6.3.3. Leukemia
- 6.3.4. Lung Cancer
- 6.3.5. Lymphoma
- 6.3.6. Multiple Sclerosis
- 6.3.7. Renal Cancer
- 6.3.8. Wet Age-related Macular Degeneration
- 6.3.9. Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)
7. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2023 Versus 2032
- 7.3. Market Segmentation
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
8. North America Targeted Therapeutics Market, 2022-2032, USD (Million)
- 8.1. Market Overview
- 8.2. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 8.3. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 8.4. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.Targeted Therapeutics Market: By Region, 2022-2032, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 8.5.1.1.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 8.5.1.1.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 8.5.1.2.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 8.5.1.2.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 8.5.1.3.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 8.5.1.3.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.5.1.1. U.S.
- 8.5.1.North America
9. UK and European Union Targeted Therapeutics Market, 2022-2032, USD (Million)
- 9.1. Market Overview
- 9.2. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 9.3. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 9.4. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.Targeted Therapeutics Market: By Region, 2022-2032, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 9.5.1.1.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 9.5.1.1.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 9.5.1.2.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 9.5.1.2.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 9.5.1.3.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 9.5.1.3.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 9.5.1.4.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 9.5.1.4.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 9.5.1.5.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 9.5.1.5.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 9.5.1.6.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 9.5.1.6.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.5.1.1. UK
- 9.5.1.UK and European Union
10. Asia Pacific Targeted Therapeutics Market, 2022-2032, USD (Million)
- 10.1. Market Overview
- 10.2. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 10.3. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 10.4. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.Targeted Therapeutics Market: By Region, 2022-2032, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 10.5.1.1.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 10.5.1.1.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 10.5.1.2.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 10.5.1.2.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 10.5.1.3.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 10.5.1.3.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 10.5.1.4.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 10.5.1.4.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 10.5.1.5.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 10.5.1.5.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 10.5.1.6.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 10.5.1.6.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.5.1.1. China
- 10.5.1.Asia Pacific
11. Latin America Targeted Therapeutics Market, 2022-2032, USD (Million)
- 11.1. Market Overview
- 11.2. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 11.3. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 11.4. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.Targeted Therapeutics Market: By Region, 2022-2032, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 11.5.1.1.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 11.5.1.1.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 11.5.1.2.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 11.5.1.2.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 11.5.1.3.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 11.5.1.3.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.5.1.1. Brazil
- 11.5.1.Latin America
12. Middle East and Africa Targeted Therapeutics Market, 2022-2032, USD (Million)
- 12.1. Market Overview
- 12.2. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 12.3. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 12.4. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.Targeted Therapeutics Market: By Region, 2022-2032, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 12.5.1.1.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 12.5.1.1.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 12.5.1.2.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 12.5.1.2.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Targeted Therapeutics Market: By Type, 2022-2032, USD (Million)
- 12.5.1.3.2. Targeted Therapeutics Market: By Application, 2022-2032, USD (Million)
- 12.5.1.3.3. Targeted Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.5.1.1. GCC
- 12.5.1.Middle East and Africa
13. Company Profile
- 13.1. Sanofi
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. GlaxoSmithKline plc
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. Takeda Pharmaceutical Company Ltd.
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. Merck & Co., Inc.
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. Novartis AG
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. Pfizer Inc.
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. F. Hoffmann-La Roche Ltd.
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. AstraZeneca
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. Seagen, Inc.
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. Bayer AG
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. Amgen, Inc.
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
- 13.12. Bristol-Myers Squibb Company
- 13.12.1. Company Overview
- 13.12.2. Financial Performance
- 13.12.3. Product Portfolio
- 13.12.4. Strategic Initiatives
- 13.13. Other Notable Players
- 13.13.1. Company Overview
- 13.13.2. Financial Performance
- 13.13.3. Product Portfolio
- 13.13.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 2 Global Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 3 Global Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 4 North America Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 5 North America Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 6 North America Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 7 U.S. Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 8 U.S. Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 9 U.S. Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 10 Canada Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 11 Canada Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 12 Canada Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 13 Rest of North America Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 14 Rest of North America Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 15 Rest of North America Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 16 UK and European Union Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 17 UK and European Union Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 18 UK and European Union Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 19 UK Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 20 UK Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 21 UK Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 22 Germany Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 23 Germany Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 24 Germany Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 25 Spain Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 26 Spain Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 27 Spain Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 28 Italy Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 29 Italy Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 30 Italy Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 31 France Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 32 France Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 33 France Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 34 Rest of Europe Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 35 Rest of Europe Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 36 Rest of Europe Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 37 Asia Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 38 Asia Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 39 Asia Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 40 China Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 41 China Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 42 China Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 43 Japan Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 44 Japan Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 45 Japan Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 46 India Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 47 India Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 48 India Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 49 Australia Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 50 Australia Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 51 Australia Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 52 South Korea Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 53 South Korea Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 54 South Korea Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 55 Latin America Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 56 Latin America Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 57 Latin America Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 58 Brazil Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 59 Brazil Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 60 Brazil Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 61 Mexico Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 62 Mexico Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 63 Mexico Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 64 Rest of Latin America Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 65 Rest of Latin America Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 66 Rest of Latin America Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 67 Middle East and Africa Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 68 Middle East and Africa Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 69 Middle East and Africa Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 70 GCC Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 71 GCC Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 72 GCC Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 73 Africa Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 74 Africa Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 75 Africa Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 76 Rest of Middle East and Africa Targeted Therapeutics Market By Type, 2022-2032, USD (Million)
- TABLE 77 Rest of Middle East and Africa Targeted Therapeutics Market By Application, 2022-2032, USD (Million)
- TABLE 78 Rest of Middle East and Africa Targeted Therapeutics Market By Distribution Channel, 2022-2032, USD (Million)
List of Figures
- FIG. 1 Global Targeted Therapeutics Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Targeted Therapeutics Market: Quality Assurance
- FIG. 5 Global Targeted Therapeutics Market, By Type, 2023
- FIG. 6 Global Targeted Therapeutics Market, By Application, 2023
- FIG. 7 Global Targeted Therapeutics Market, By Distribution Channel, 2023
- FIG. 8 Global Targeted Therapeutics Market, By Geography, 2023
- FIG. 9 Market Geographical Opportunity Matrix - Global Targeted Therapeutics Market, 2023
FIG. 10Market Positioning of Key Targeted Therapeutics Market Players, 2023
FIG. 11Global Targeted Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
- FIG. 12 Global Targeted Therapeutics Market, By Type, 2023 Vs 2032, %
- FIG. 13 Global Targeted Therapeutics Market, By Application, 2023 Vs 2032, %
- FIG. 14 Global Targeted Therapeutics Market, By Distribution Channel, 2023 Vs 2032, %
- FIG. 15 U.S. Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 16 Canada Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 17 Rest of North America Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 18 UK Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 19 Germany Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 20 Spain Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 21 Italy Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 22 France Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 23 Rest of Europe Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 24 China Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 25 Japan Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 26 India Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 27 Australia Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 28 South Korea Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 29 Rest of Asia Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 30 Brazil Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 31 Mexico Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 32 Rest of Latin America Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 33 GCC Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 34 Africa Targeted Therapeutics Market (US$ Million), 2022 - 2032
- FIG. 35 Rest of Middle East and Africa Targeted Therapeutics Market (US$ Million), 2022 - 2032
